Immunome is developing targeted cancer therapies; on August 7, 2025, the EMA granted Orphan Drug Designation to varegacestat, and the FDA also granted the designation.
3 reports, 3 independent
Updated Fri 00:00
No new developments lately
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Immunome is developing targeted cancer therapies; on August 7, 2025, the EMA granted Orphan Drug Designation to varegacestat, and the FDA also granted the designation.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.EMA validated MAA for varegacestat, a drug from Immunome, following ASCO presentation.1 source
Immunome's varegacestat received Orphan Drug Designation from both the EMA and the FDA.1 source
Keep exploring
The entities involved
-
Immunome (United States)
company in Philadelphia, United States
Nothing else this week.
-
Food and Drug Administration
government organization in Nonthaburi, Thailand
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- empr.com
- Business WireImmunome Reports Second Quarter 2025 Financial Results and Provides Business Update BOTHELL, Wash., August 06, 2025--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on